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Important challenges for the diagnosis and monitoring of mild traumatic brain injury (mTBI)
include the development of plasma biomarkers for assessing neurologic injury, monitor-
ing pathogenesis, and predicting vulnerability for the development of untoward neurologic
outcomes. While several biomarker proteins have shown promise in this regard, used indi-
vidually, these candidates lack adequate sensitivity and/or specificity for making a definitive
diagnosis or identifying those at risk of subsequent pathology. The objective for this study
was to evaluate a panel of six recognized and novel biomarker candidates for the assess-
ment of TBI in adult patients. The biomarkers studied were selected on the basis of their
relative brain-specificities and potentials to reflect distinct features of TBI mechanisms
including (1) neuronal damage assessed by neuron-specific enolase (NSE) and brain derived
neurotrophic factor (BDNF); (2) oxidative stress assessed by peroxiredoxin 6 (PRDX6); (3)
glial damage and gliosis assessed by glial fibrillary acidic protein and S100 calcium binding
protein beta (S100b); (4) immune activation assessed by monocyte chemoattractant pro-
tein 1/chemokine (C–C motif) ligand 2 (MCP1/CCL2); and (5) disruption of the intercellular
adhesion apparatus assessed by intercellular adhesion protein-5 (ICAM-5). The combined
fold-changes in plasma levels of PRDX6, S100b, MCP1, NSE, and BDNF resulted in the
formulation of a TBI assessment score that identified mTBI with a receiver operating char-
acteristic (ROC) area under the curve of 0.97, when compared to healthy controls. This
research demonstrates that a profile of biomarker responses can be used to formulate
a diagnostic score that is sensitive for the detection of mTBI. Ideally, this multivariate
assessment strategy will be refined with additional biomarkers that can effectively assess
the spectrum of TBI and identify those at particular risk for developing neuropathologies
as consequence of a mTBI event.
Keywords: biomarkers, assessment score, human, mild traumatic brain injury, multivariate analysis
INTRODUCTION
Mild traumatic brain injury (mTBI) is a major problem for civilian
and military clinicians alike and is often described as an invisible
wound (1). Such an injury can precipitate a cascade of intracere-
bral events that include hypoxia, oxidative stress, necrosis, apop-
tosis, and chronic inflammation (2–4). These processes may be
initiated in the absence of any acute clinical signs (5, 6). While
many patients never exhibit overt clinical signs of mTBI, a sub-
set of mTBI cases, estimated to be up to 20%, proceed to develop
injury-related pathologies over time (7, 8). Accordingly, a long-
sought goal for the treatment of mTBI is the identification of
patients who are at risk of developing long-term complications. A
missed diagnosis of TBI undermines the opportunity for imme-
diate clinical treatments and masks the need for behavioral mea-
sures designed to prevent the occurrence of a second head injury
(9). Additionally, missed diagnoses are key factors hindering
preclinical and clinical TBI investigations (10, 11).
Clinical assessment for TBI routinely involves acute injury sur-
veillance, neuropsychological testing, brain imaging, and record-
ing of signs and symptoms (9, 12, 13). By definition, however,
none of these methods are sensitive for the diagnosis of mTBI
(14, 15). For more than a decade, a large effort has focused on
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the identification of blood-borne biomarkers that are capable of
revealing the otherwise invisible injury of mTBI (16). Unfortu-
nately, the success of these endeavors has been limited and at
present, the biomarker strategy has yet to produce a diagnostic tool
that is sensitive and specific for the identification of mTBI (17–
21). Key factors limiting the success of these efforts have included
the lack of candidates for investigation as well as the focus of
many studies on the potential of just a single candidate as being
informative in mTBI (20, 22–28).
The present project has drawn upon the knowledge of recog-
nized TBI biomarker candidates as well as two new candidates;
peroxiredoxin 6 (PRDX6) and intercellular adhesion molecule-
5/telencephalin (ICAM-5, TLN), for the development of a multi-
variate analytical approach for the simultaneous assessment of a
panel of biomarkers for mTBI (29, 30). This strategy is based upon
the proposal that the collective information derived of a multi-
variate approach mitigates the shortcomings of an individual bio-
marker that may include limited specificity and/or sensitivity. Each
candidate biomarker was selected for its relative brain-specificity
and potential to reflect distinct features of TBI mechanisms: (1)
neuronal damage and recovery assessed by neuron-specific enolase
(NSE) (31–33) and brain derived neurotrophic factor (BDNF) (34,
35); (2) oxidative stress assessed by PRDX6 (30, 36); (3) glial dam-
age and gliosis assessed by glial fibrillary acidic protein (GFAP)
and S100 calcium binding protein beta (S100b) (33, 37); (4)
immune activation assessed by monocyte chemoattractant pro-
tein 1/chemokine (C–C motif) ligand 2 (MCP1/CCL2) (38, 39);
and (5) disruption of the intercellular adhesion apparatus assessed
by ICAM-5 (40, 41).
The findings presented here demonstrate that fold increases
in plasma levels of NSE, PRDX6, S100b, BDNF, and MCP1 bio-
markers in adult subjects experiencing mTBI may be formulated
to produce an informative TBI assessment score (TBIAS). This
TBIAS effectively differentiated between control and mild TBI
with improved sensitivity and specificity over that provided by
any of the individual biomarkers. It is proposed that the strategy
of multivariate analysis can be further developed and refined for
both the acute diagnosis of mTBI and the identification of patients
who are at risk for developing subsequent clinical complications.
MATERIALS AND METHODS
CLINICAL SAMPLES AND INSTITUTIONAL REVIEW BOARD APPROVALS
Human plasma samples analyzed here were collected as part
of two separate clinical studies. The first study, conducted by
the National Institute of Neurological Disorders and Stroke
(NINDS) of the National Institutes of Health (NIH; Bethesda,
MD, USA), investigated suspected TBI in civilians presenting to
the emergency department of two Washington DC metropol-
itan hospitals. The NINDS/NIH/Center for Neuroscience and
Regenerative Medicine (CNRM) study was approved by the Cen-
tral Neuroscience Institutional Review Board (IRB), NIH, the
Medstar IRB, Washington DC, USA, and administrative review
approval by the Uniformed Services University of the Health Sci-
ences IRB (Bethesda, MD, USA). Following de-identification, the
NINDS samples and data were provided through the Center for
Neuroscience and Regenerative Medicine Biorepository. A pri-
mary objective of the NINDS/NIH study (NCT01132937) was
to study the magnetic resonance imaging (MRI) results of
individuals who had recently had head injury and suspected
traumatic brain injury. Accordingly, blood samples were col-
lected at the times of research neuroimaging: first, upon pre-
sentation to the hospital and within 48 h of injury; and sec-
ond, at a second imaging time ranging between 2 and 7 days
post-injury.
The second study, conducted in collaboration with Defence
Research and Development Canada, Sunnybrook Health Sciences
Centre, St. Michael’s Hospital, and the Department of Surgery
and Critical Care Medicine, University of Toronto (all in Toronto,
Canada), investigated both healthy volunteers and civilian trauma
patients presenting with an isolated moderate-to-severe head
injury. The Canadian component of the study was approved by
the local REBs of the participating institutions. The biomarker
analyses presented here were approved by the Uniformed Services
University of the Health Sciences IRB.
This investigation involved two separate sets of control sam-
ples. The control samples for the study of mild–moderate TBI
consisted of 30 normal adult, age and gender matched, healthy vol-
unteers obtained commercially from Innovative Research (Novi,
MI, USA). Control samples for the moderate–severe TBI study
consisted of 44 age, gender and race-matched healthy control sam-
ples that were collected onsite at the same treatment center where
the TBI samples were collected.
BIOMARKER ANALYSES
A multiplex assay platform developed for the simultaneous analy-
sis of BDNF, S100b, NSE, GFAP, MCP-1/CCL2, and ICAM-5 in
samples of human plasma was used. Plasma levels of PRDX6 were
measured using a single-plex assay system.
TBI 6-PLEX ASSAY PLATFORM
A multiplex analytical platform for six candidate TBI biomarkers
(TBI 6-Plex) was established on SECTOR® Imager 6000 reader
plates [Meso Scale Discovery (MSD)], Gaithersburg, MD, USA)
using the commercially available antibodies and calibrant proteins
listed in Table 1.
Capture antibodies were printed [20µg/mL in phosphate
buffered saline (PBS)] at addressable locations in the wells of
standard-bind multiplex assay plates (MSD proprietary print-
ing service). All detection antibodies were derivatized with elec-
trochemiluminescent SULPHO-Tag NHS-ester R91AN-1 using
SULPHO-Tag reagent and procedures provided by MSD. Stock
solutions of protein standards (30×) and SULPHO-Tag detec-
tion antibodies (10×, 60µg/mL) were prepared in PBS-1% bovine
serum albumin (BSA) and stored at −80°C as single use aliquots.
The standard protocol for performing the multiplex assay was
as follows. Plates were hydrated for 60 min at room tempera-
ture with 25µL PBS-1% BSA containing immunoglobulin block-
ers [goat IgG 0.1% (Kerrville, TX, USA)], mouse IgG 0.02%
and rabbit IgG 0.1% (Rockland, Gilbertsville, PA). Samples were
diluted in an equal volume of PBS-1% BSA and added directly
into the wells in a volume of 25µL. Standard curves were sim-
ilarly prepared in buffer containing chicken plasma (1:1 dilu-
tion in PBS-1% BSA; Innovative Research, Inc.), which served
as an off-species matrix to control for the non-specific effects
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Table 1 |TBI 6-Plex assay reagents.
Reagent BDNF GFAP MCP1/CCL2 ICAM-5 NSE S100b
Capture antibody Vendor R&D Genway R&D R&D R&D Sigma
Catalog # MAB848 20-272-190050 MAB679 MAB1950 MAB5169 S2532
Protein calibrant Vendor R&D Calbiochem (EMD) R&D R&D Abnova Sigma
Catalog # 2488D005 345996 279-MD-010 1950-M5 H00002026-P01 S6677
Detection antibody Vendor R&D DAKO R&D R&D R&D Genway
Catalog # MAB648 Z0334 AF-279-NA AF1950 AF5169 18-272-198528
R&D: R&D Systems Inc., Minneapolis, MN, USA.
Sigma: Sigma Aldrich, St Louis, MO, USA.
Genway: GenWay Biotech Inc., San Diego, CA, USA.
Calbiochem (EMD): Calbiochem, San Diego, CA, USA.
Abnova: Abnova, Walnut, CA, USA.
DAKO: DAKO, Carpinteria, CA, USA.
Table 2 | Effects of sample matrix on the lower limit of quantitation
and detection (LOQ/LOD) ofTBI biomarkers measured by theTBI
6-Plex platform.
Analyte Buffer only Plasma matrix
LOQ/LOD LOQ/LOD
BDNF 0.17/0.08 0.06/0.03
GFAP 0.26/0.20 0.27/0.21
NSE 0.24/0.07 0.87/0.28
S100b 0.06/0.02 0.39/0.13
ICAM-5 0.21/0.12 0.51/0.42
MCP1/CCL2 0.003/0.002 0.015/0.015
LOQ is defined as the biomarker concentration represented by the mean signal
for zero concentration plus 10 times the SD of this mean.
LOD is defined as the biomarker concentration represented by the mean signal
for zero concentration plus three times the SD of this mean.
Values=ng/mL.
n=6 replicates per standard curve concentration.
Data are representative of three replicate experiments.
of human plasma. In comparison to other matrices tested (cow,
donkey, goat, guinea pig, horse, pig, rabbit; Innovative Research,
Inc.), chicken plasma exhibited a low background signal regard-
less of the volume of matrix assayed, and resulted in stan-
dard curves that matched those of human sample containing
equal amounts of calibrant. The effects of matrix on the per-
formance of each assay are presented in Table 2. Matrix min-
imally altered the sensitivity of each assay without affecting its
dynamic range.
Plates were shaken at room temperature for 2 h and then incu-
bated at 4°C overnight. Wells were washed three times with PBS
containing 0.05% Tween-20 (PBS-T) and then incubated for 1 h
with a blended mixture of SULPHO-Tagged detection antibodies
diluted to 2µg/mL each in PBS-1% BSA (25µL/well). The plates
were then washed three times with PBS-1% BSA, developed with
the addition of MSD Read Buffer (150µL/well) and read in a
SECTOR Imager 6000 Reader (MSD). Lower limits of detection
(LOD) and lower limits of quantitation (LOQ) were defined for
each assay as 3 times and 10 times the SD of the averaged 0 for each
assay, respectively (n= 10 for three replicate experiments). Simi-
larly, intra- and inter-assay variability was <3 and 10% respectively,
for all assays. All control values for S100b were detected within the
range between the LOD and LOQ for the assay, with some rising
to the LOQ. Plasma levels of S100b in all post-injury samples were
well above the LOQ for the assay. Accordingly, the LOD value was
assigned to control samples that did not reach the LOQ.
PRDX6 SINGLE-PLEX ASSAY PLATFORM
The single-plex immunosorbent assay was developed using MSD
standard-bind electrochemiluminescence microtiter plates. Com-
binations of seven monoclonal and five polyclonal anti-PRDX6
antibodies were screened for compatible pairs. A mouse anti-
PRDX6 monoclonal antibody (Clone 1A11, GenWay Biotech,
catalog #20-007-280008, San Diego, CA, USA) and a rabbit mono-
clonal anti-PRDX6 antibody (Clone EPR3755, Epitomics, catalog
# 2769-1, Burlingame, CA, USA) were optimized as capture and
primary antibodies, respectively. The monoclonal capture anti-
body was purified by Protein G affinity chromatography (Protein
G HP SpinTrap, GE Healthcare, Uppsala, Sweden, vendors pro-
tocol) to remove glycerol, and then coated to the plates at a
concentration of 4µg/mL in PBS (25µL/well,overnight,4°C). The
plates were blocked with 3% BSA in PBS for 2 h at room tempera-
ture. The wells were then washed three times with PBS containing
0.05% PBS-T and the plasma samples (diluted 1:4 in PBS-1%
BSA) were added to wells in a total volume of 100µL/well. The
standard curves were established using serial dilutions of PRDX6
recombinant human protein (GenWay Biotech, catalog #GWB-
F65D50, San Diego, CA, USA) in a final volume of 100µL/well.
Standard curves were prepared in PBS-1% BSA containing 25%
chicken plasma (Innovative Research, Inc.) to control for the non-
specific effects of serum or plasma matrix. Plates were incubated
for 2 h at room temperature and washed three times in PBS-T.
Following the addition of primary antibody (2µg/mL in PBS-1%
BSA, 25µL/well), plates were incubated for 1 h at room temper-
ature and washed three times in PBS-T. The plates were then
treated with goat anti-rabbit MSD SULFO-Tag antibody (MSD,
R32AB-1) (2µg/mL in PBS-1% BSA, 25µL/well, and 60 min at
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room temperature). After three PBS-T washes, the plates were
developed with 150µL/well of MSD Read Buffer T with Surfac-
tant (MSD) and electrochemiluminescence read using a SECTOR
Imager 6000 (MSD). The assay can detect 0.7 ng/mL (lower limit
of detection; LOD) and is quantitative to 1 ng/mL (lower limit of
quantitation, LOQ) as defined by 3 and 10 times the SD of read-
ings obtained for 0 pg/mL standard, respectively (n= 10). Values
for LOD and LOQ were marginally lower (50%) in the absence of
matrix (buffer only). All sample values fell within the linear range
of the standard curve. Intra- and inter-assay variability were 4 and
13%, respectively (n= 10).
STATISTICAL ANALYSES
Multivariate analysis of variance (MANOVA) was conducted on
plasma levels of seven proteins for each clinical study separately.
Violations of normality and homogeneity were addressed using
log transformations and adjustments were made to the model
to account for difference in sample size between controls and
TBI subjects. Additional analyses were conducted to determine
differences based on demographics using MANOVA.
The TBIAS was derived first by calculating fold-changes based
on the control values and then adding those fold-changes for each
marker. Additional MANOVAs were conducted to test the TBIAS
model. Ability of the TBIAS to properly classify TBI versus control
cases was assessed using receiver operating characteristic (ROC)
curves and area under the curve (AUC) analyses for each time
point.
RESULTS
PATIENT DEMOGRAPHICS CLINICAL STUDY INVESTIGATING MILD TO
MODERATE TBI
The NINDS/NIH/CNRM study enrolled 154 subjects with head
trauma: direct head impact 54% (83 patients), falls 28% (43
patients), acceleration/deceleration injuries (mainly automobile
accidents) 12% (18 patients), and other 7% (10 patients). Inclu-
sion and exclusion criteria for this study are presented in Table S1
in Supplementary Material. The median Glasgow coma scale score
at the time of admission was 15. Clinical data also included infor-
mation concerning loss of consciousness, post-traumatic amnesia,
computed tomography (CT) scan, and MRI results. An analy-
sis of the available CT and MRI data revealed that 51% (79
patients) of the TBI subjects presented with no discernable CT or
MRI abnormalities, whereas 23% (36 patients) presented with CT
and MRI abnormalities and 16% (24 patients) with MRI imag-
ing abnormalities. No imaging data were available on 10% (15
patients). The cohort of subjects with imaging findings related to
moderate TBI had a median Glasgow coma scale score of 14 and
periods of loss of consciousness and post-traumatic amnesia inter-
vals consistent with mild TBI (<30 min and ≤24 h, respectively).
However, based upon the accepted guidelines for clinical classifi-
cation, the subset of image-positive subjects was classified here as
having moderate TBI (n= 60), and the remaining image-negative
subjects (n= 79) were classified as having experienced a mild TBI
(42). Patient demographics and clinical data are presented in detail
in Table S2 in Supplementary Material. Control samples for com-
parison were obtained commercially from Innovative Research
(Novi, MI, USA).
PATIENT DEMOGRAPHICS FOR THE CLINICAL STUDY INVESTIGATING
MODERATE TO SEVERE TBI
This study involved a total of 106 subjects who were admit-
ted with isolated head injuries and diagnosed with moderate
to severe TBI. Inclusion and exclusion criteria for this study
are presented in Table S1 in Supplementary Material. Plasma
samples were obtained at admission into the emergency depart-
ment and at 6, 12, and 24 h post-injury. Glasgow coma scale
scores on admission were all below 12 (range= 3–12; mean= 6;
median= 6) and 26 of 106 subjects died within 24 h following
admission. A total of 44 control samples were collected as part of
this study from non-trauma, non-post-traumatic stress disorder
military personnel. The demographic and clinical data available
from this study were limited as compared to the data recorded
in the mild to moderate TBI study. Patient demographics and
clinical data are presented in detail in Table S3 in Supplementary
Material.
EFFECTS OF MILD TO MODERATE TBI ON PLASMA LEVELS OF
CANDIDATE BIOMARKER PROTEINS
Of the 154 subjects, 45 did not have imaging and/or plasma sam-
ples at all-time points. Therefore, they were not included in the
initial analyses. Table 3 presents the mean plasma levels of all 7
biomarker for the remaining 109 TBI subjects. Statistical compar-
isons between control and TBI data were made using a MANOVA.
Importantly, plasma biomarker responses were not different in
Table 3 | Plasma levels of candidateTBI biomarker proteins in subjects with mild to moderateTBI and controls.
Condition ng/mL BDNF ICAM-5 MCP1/ NSE S100b PRDX6 GFAP
CCL2
Control Mean 2.8 0.9 0.1 30.0 0.2 78.2 <0.3
SEM 0.6 0.1 0.0 6.2 0.0 17.5 –
Admission Mean 9.1 0.9 0.2 55.5 0.7 388.0 <0.3
SEM 0.6 0.0 0.0 2.8 0.1 15.0 –
p= <0.0001 NS <0.001 <0.0001 <0.03 <0.0001 –
2–7 days Mean 9.4 0.9 0.2 67.3 0.6 430.8 <0.3
SEM 0.6 0.0 0.0 3.3 0.1 15.8 –
p= <0.0001 NS <0.001 <0.0001 <0.03 <0.0001 –
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subjects who had positive neuroimaging findings (n= 43) ver-
sus those who did not [n= 79; F(6, 128)= 0.0658, p> 0.05].
Accordingly, all TBI subjects were combined together for fur-
ther analyses. The overall multivariate model was significant for
each time point [TP1: F(6, 128)= 47.33, p< 0.001; TP2: F(7,
111)= 40.09, p< 0.001] with effect size >0.14 and observed power
of 1.0. The statistical data presented in Table 3 indicate that blood
levels of BDNF, MCP1/CCL2, NSE, S100b, and PRDX6 were sig-
nificantly greater in TBI subjects as compared to controls. Blood
levels of GFAP were consistently below the level of quantification
for all subjects and all-time points. Finally, there were no differ-
ences in circulating levels of ICAM-5 between the control and TBI
subjects.
The effects and interactions among demographic variables
and neurological findings on plasma biomarker responses were
evaluated by MANOVA. As noted above for neuroimaging, when
co-varying for gender, race, age, and education, there was no over-
all difference between males and females and no differences with
regard to race and education. Younger subjects (<45 years) had
modestly lower levels of MCP1/CCL2 at admission as compared
to levels measured in older (>45 years) individuals (p> 0.05).
No other biomarkers showed this pattern. Changes in the lev-
els of plasma biomarkers did not reflect the nominal differences
observed in admission Glasgow coma scale or CT/MRI imaging
results.
Figure 1 shows the time-related fold increases in mean plasma
levels observed for BDNF, ICAM 5, MCP1/CCL2, NSE, S100b, and
PRDX6 following mild to moderate TBI.
EFFECTS OF MODERATE TO SEVERE TBI ON PLASMA LEVELS OF
CANDIDATE BIOMARKER PROTEINS
Table 4 presents the mean plasma levels for all biomarkers at
all-time points for TBI subjects and control subjects compris-
ing the moderate to severe study. Compared to control values,
circulating levels of all biomarkers were increased in response to
moderate to severe TBI. While the mean levels of GFAP in the
TBI group rose into the detectable range following moderate to
severe TBI, the statistical significance of this response could not
be calculated because control values were below the limit of detec-
tion. Blood levels of all other markers were significantly increased
following TBI.
Figure 2 shows the time course for the fold-changes in plasma
levels of candidate biomarker proteins following moderate to
severe TBI. Time-related increases (p< 0.05) in plasma levels were
observed for five of the seven candidate biomarker proteins: BDNF,
MCP1/CCL2, NSE, S100b, and PRDX6, whereas, circulating lev-
els of ICAM-5 were not altered. A fold-change in blood levels of
GFAP could not be calculated because control values were below
the limit of detection.
FIGURE 1 | Effects of mild to moderateTBI on plasma levels of
candidate biomarker protein expressed as fold-changes from controls
values. SeeTable 3 for statistical significance (p values).
Table 4 | Plasma levels of candidateTBI biomarker proteins in subjects with moderate to severeTBI.
Condition ng/mL BDNF ICAM-5 MCP1/ NSE S100b PRDX6
CCL2
Control Mean 1.2 1.4 0.1 10.5 0.3 144.5
SEM 0.2 0.1 0.0 0.9 0.0 24.2
Admission Mean 4.5 1.1 0.4 120.0 2.5 762.9
SEM 0.5 0.1 0.1 10.0 0.6 85.5
p= <0.001 <0.08 <0.001 <0.001 <0.001 <0.001
6 h Mean 4.0 1.0 0.3 110.8 0.6 510.5
SEM 0.4 0.1 0.1 9.3 0.1 53.2
p= <0.001 <0.001 <0.001 <0.001 <0.002 <0.001
12 h Mean 3.3 1.0 0.2 100.4 0.6 413.2
SEM 0.4 0.1 0.0 9.3 0.1 43.5
p= <0.001 <0.001 <0.001 <0.001 <0.01 <0.001
24 h Mean 2.3 1.0 0.3 69.2 0.6 280.0
SEM 0.3 0.1 0.0 7.4 0.2 44.4
p= <0.001 <0.001 <0.005 <0.001 <0.07 <0.006
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FORMULATION OF A TBI ASSESSMENT SCORE
The distinctive profiles observed in blood levels of biomarker pro-
teins following TBI suggested that these patterns could contribute
to formulation of a biomarker signature for the diagnosis of TBI.
Tables 5 and 6 present fold-changes over control values in bio-
markers proteins observed at the time of admission for the mild to
moderate and moderate to severe TBI studies, respectively. Table 7
shows the formulation of a TBIAS, which is based upon the sum-
mation of the fold-changes observed in plasma levels of BDNF,
MCP1/CCL2, NSE, S100b, and PRDX6. Because control values are
fixed by condition, each of biomarkers was assigned a value of one,
for a summation control score of five. In the case of mTBI, a sum-
mation score of 17 was calculated for the composite fold-changes
in candidate biomarkers. In the case of moderate to severe TBI, the
FIGURE 2 | Effects of moderate to severeTBI on plasma levels of
candidate biomarker proteins expressed as fold-changes from control
values.
summation score was 32. Calculated in this fashion, the TBIAS dis-
tinguishes mTBI from controls and from moderate to severe TBI.
To differentiate TBI from control subjects, receiver operating
characteristic (ROC) curves were calculated for time point 1 (TP1;
ED admission; Figure 3) and time point 2 (2–7 days post-injury;
Figure 4). Accuracy of such a test is reflected by the AUC where
an area of 1.0 represents a perfect test and an AUC above 0.9 is
considered excellent. The AUC for the TBIAS at time point one
was 0.974 (SE.011) while the next highest biomarker was PRDX6
(0.935/0.019). At time point two (TP2) 2–7 days post-injury, the
AUC for the TBIAS was 0.987 (0.007) while the next highest bio-
marker was again PRDX6 (0.967/0.012). To test the accuracy of
the TBIAS for mTBI, subjects with positive imaging results were
removed from the data and ROC curves were recalculated. There
was no change in the AUC.
DISCUSSION
Despite significant scientific effort investigating the mechanisms
and neuropathology of TBI, no biomarkers have been estab-
lished for diagnosing milder forms of TBI, assessing its underlying
mechanisms, identifying effective therapeutic targets, or predict-
ing future risks (13, 21, 43, 44). In this regard, it has been proposed
that a biomarker signature based upon multiple biomarker candi-
dates can improve the diagnosis and monitoring of mTBI (13, 28).
The present investigation demonstrates that five of the biomark-
ers studied here can be used to establish a signature that identifies
mTBI with a quantitative assessment score. Because the assessment
score is based upon definitive measures of circulating biomarkers,
it provides an objective assessment that is easily standardized
across clinical settings.
The present study demonstrates how a profile of biomarker
responses can be combined in a simplistic manner to create an
informative assessment score that identifies mTBI. This assess-
ment score is based upon fold-changes in plasma levels of both
recognized and novel biomarker proteins measured in humans
Table 5 | Mean plasma values and respective fold-change in values of candidateTBI biomarker proteins in subjects with mild to moderateTBI.
BDNF ICAM-5 MCP1/CCL2 NSE S100b PRDX6 GFAPa
Control 2.8±0.6 0.9±0.1 0.1±0.0 30.0±6.2 0.2±0.0 78.0±17.5 <0.3
TBI admission 9.1±0.6 0.9±0.0 0.2±0.0 55.5±2.8 0.7±0.1 388.0±15.0 <0.3
Fold-change 3 No ∆ 2 2 5 5 –
aNo fold-change could be calculated for GFAP because all values in both control and TBI groups were below the level of quantification.
Table 6 | Mean plasma values of candidateTBI biomarker proteins in moderate to severeTBI subjects and their respective fold-changes
compared to controls.
BDNF ICAM-5 MCP1/CCL2 NSE S100b PRDX6 GFAPa
Control 1.2±0.2 1.4±0.1 0.1±0.0 10.0±0.9 0.3±0.0 145.0±24.0 <0.3
TBI admission 4.5±0.5 1.1±0.1 0.4±0.1 120.0±10.0 2.5±0.6 763.0±85.0 3.8±1.5
Fold-change 4 No ∆ 3 11 9 5 –
aNo fold-change could be calculated for GFAP because control values were below the level of quantification.
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Table 7 | Formulation of aTBI assessment score.
Protein Control Mild to moderate Moderate to severe
BDNF 1 3 4
MCP1/CCL2 1 2 3
NSE 1 2 11
S100b 1 5 9
PRDX6 1 5 5
TBI score 5 17 32
experiencing mild to moderate TBI. It is generally held that when
considered individually, none of the proteins involved have proven
universally informative in the diagnosis of milder forms of TBI
(28). The present data suggest that a multivariate analysis may
result in a diagnostic tool having improved clinical utility for mild
TBI. While the TBIAS distinguishes between the milder versus
severe forms of TBI, the most important use for this type of analysis
will be in the assessment of mTBI where definitive imaging data
cannot be obtained.
FIGURE 3 | Individual receiver operating characteristic curves for time
point 1 (TP1)TBI assessment scores from the mild to moderate
cohort. The red line demonstrates the combined TBI assessment score
ROC curves for five TBI Biomarkers. Note the high sensitivity and
specificity [AUC 0.97 95% CI (0.95–0.99)] when comparing individual
biomarkers as a collective.
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FIGURE 4 | Receiver operating characteristic (ROC) curves for the
assessment scores for the mild to moderateTBI cohort at 2–7days
post-injury [time point 2 (TP2)]. The blue line represents the combined TBI
assessment score ROC curve (TP2_TBI_Score), for data derived from all five
biomarker candidates. Highest sensitivity and specificity [AUC 0.987 95% CI
(0.97–1.0)] were observed when considering all five biomarkers collectively.
The multivariate approach used here evaluates proteins selected
for their potential to detect injury and classify clinical outcomes
in an acute, subclinical phase. Important strengths of multi-
plex analysis used here include conservation of precious samples
and the ability to simultaneously evaluate, under identical assay
conditions, a panel of analytes that can together provide insights
into a variety of components of an injury, which in this case include
neuronal injury [NSE, ICAM-5, BDNF; (45, 46)], glial activation
and injury [GFAP, S100b; (47, 48)], oxidative stress [PRDX6; (49,
50)], and neuroinflammation [MCP1/CCL2; (51)].
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Consistent with other studies, the present findings indicate that
blood levels of TBI biomarkers generally increase very quickly to a
maximum within 24 h post-injury (52–55). After this period, how-
ever, the profile of biomarker proteins in blood varies over time,
presumably reflecting different rates of production and clearance
for each protein (Figures 1 and 2). While the acute post-injury
sample provides a relatively standardized time point for clini-
cal comparisons, samples collected at later times post-injury may
prove informative in the assessment of patient-specific pathogenic
processes (56, 57).
This study has several limitations. First, the study has a modest
sample size and will need to be validated in a larger independent
cohort. Second, the study design focused on the evaluation of acute
TBI and did not determine the relations that may exist between an
acute biomarker signature and the development of longer-term
complications or increased susceptibility to a subsequent mTBI
resulting in a second injury syndrome. Third, given the unex-
pected nature of TBI, pre-injury blood samples were not available.
Accordingly, baseline measures were derived from the analysis of
standardized control samples. While this approach provides for
an important comparison across studies, within-subject responses
are unavailable for individualized diagnoses. Fourth, due to the
acute nature of the study designs, it was not possible to identify
those at particular risk for developing neuropathologies as a conse-
quence of a mTBI event. Lastly, this investigation is limited by the
selection of the candidate biomarkers for study. The present panel
of proteins can certainly be improved upon with the inclusion
of additional biomarker candidates; both recognized and newly
discovered, which together may offer greater diagnostic sensitivity
and specificity as well as important clinical insight into underlying
mechanisms and potential long-term consequences of a mTBI.
While not often emphasized, it should be recognized that
many, if not all of the candidate TBI biomarkers currently under
investigation are not strictly brain-specific. For example, GFAP is
expressed in the gastrointestinal tract and the liver (58), BDNF and
NSE are concentrated in platelets (59, 60) and S100b is expressed
in adipocytes and the GI tract (61, 62). Similarly, ubiquitin carboxy
terminal hydrolase-L1 (UCH-L1, PGP9.5), an emerging prototype
TBI biomarker, is expressed in the endometrium and secretory
cells of the pituitary gland (63–66). Accordingly, the concept of a
brain-specific response must be qualified when considering TBI
biomarker proteins and should include the potential contribu-
tion of poly trauma to a biomarker signature. In this regard, an
additional strength in a panel of TBI biomarkers is that it can pro-
vide a multi-dimensional view of a brain injury, avoiding possible
confounding variables that may result from poly trauma and the
assessment of a single biomarker (67).
In conclusion, this research demonstrates that a profile of blood
biomarker responses can be used to formulate a novel diagnos-
tic score “TBIAS” that is sensitive for the detection of mTBI.
Ideally, this multivariate TBIAS will be refined with the discov-
ery of additional sensitive and specific biomarkers that can assess
the entire spectrum of a TBI including physical injury, metabolic
dysfunction, oxidative stress, neuroinflammation, and changes in
cerebrovascular regulation (Figure 5). Ideally, a multivariate bio-
marker signature will also be able to identify those at particular
risk for developing serious neuropathologies as consequence of
FIGURE 5 |The Glasgow coma scale (GCS) was designed to assess
levels of consciousness. Accordingly, its clinical use focuses on the more
severe forms of TBI. A TBI assessment score (TBIAS) may be used to
assess the entire spectrum of TBI providing information on specific
pathogenic mechanisms that may be unique to an individual’s injury.
a subsequent mTBI event. Overall, the TBIAS strategy discussed
here has potential for clinical decision-making and for monitoring
the progression of injury and/or recovery. As such, a TBIAS could
have a role in managing patients at high-risk of repeated injury
and may be incorporated into guidelines for return to work, duty,
or play.
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